BCAX
Bicara Therapeutics·NASDAQ
--
--(--)
--
--(--)
BCAX fundamentals
During Q3 2025, Bicara Therapeutics (BCAX) reported revenue of --, a YoY change of 0.00%. Net income was -36.33M, a YoY change of -107.83%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 9.53M -- | 13.69M -- | 15.37M -- | 19.75M -- | 20.63M +116.45% | 26.64M +94.62% | 41.79M +171.81% | 32.02M +62.12% | 40.68M +97.19% | 141.12M -- |
Selling, General and Administrative Expenses | 2.59M -- | 3.13M -- | 3.34M -- | 3.91M -- | 4.76M +83.87% | 6.75M +116.13% | 7.46M +123.07% | 7.22M +84.70% | 7.70M +61.65% | 29.13M -- |
General and Administrative Expenses | 2.59M -- | 3.13M -- | 3.34M -- | 3.91M -- | 4.76M +83.87% | 6.75M +116.13% | 7.46M +123.07% | 7.22M +84.70% | 7.70M +61.65% | 29.13M -- |
Research and Development Expenses | 6.94M -- | 10.56M -- | 12.03M -- | 15.84M -- | 15.86M +128.62% | 19.88M +88.25% | 34.33M +185.35% | 24.80M +56.54% | 32.98M +107.86% | 111.99M -- |
Operating Income | -9.53M -- | -13.69M -- | -15.37M -- | -19.75M -- | -20.63M -116.45% | -26.64M -94.62% | -41.79M -171.81% | -32.02M -62.12% | -40.68M -97.19% | -141.12M -- |
Non-Operating Income (Loss) | -13.31M -- | 1.25M -- | 2.87M -- | 2.70M -- | 3.15M +123.63% | 5.87M +368.53% | 5.01M +74.89% | 4.68M +73.34% | 4.39M +39.37% | 19.95M -- |
Gain (Loss) on Change in Fair Value | -13.33M -- | -49.00K -- | -- -- | -- -- | -- -- | 0 +100.00% | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -13.00K -- | -1.30M -- | -2.87M -- | -2.70M -- | -3.15M -24107.69% | -5.87M -350.88% | -5.01M -74.89% | -4.68M -73.34% | -4.39M -39.37% | -19.95M -- |
Interest Income | 13.00K -- | 1.30M -- | 2.87M -- | 2.70M -- | 3.15M +24107.69% | 5.87M +350.88% | 5.01M +74.89% | 4.68M +73.34% | 4.39M +39.37% | 19.95M -- |
Pretax Income From Continuing Operations | -22.84M -- | -12.44M -- | -12.51M -- | -17.05M -- | -17.48M +23.48% | -20.77M -67.04% | -36.77M -194.03% | -27.34M -60.34% | -36.29M -107.60% | -121.17M -- |
Income Tax Expense | -- -- | 5.00K -- | 1.00K -- | -- -- | 0 -- | 186.00K +3620.00% | 72.00K +7100.00% | 52.00K -- | 40.00K -- | 350.00K -- |
Net Income | -22.84M -- | -12.44M -- | -12.51M -- | -17.05M -- | -17.48M +23.48% | -20.96M -68.46% | -36.85M -194.58% | -27.39M -60.64% | -36.33M -107.83% | -121.52M -- |
Net Income Attributable to Owners of the Company | -22.84M -- | -12.44M -- | -12.51M -- | -17.05M -- | -17.48M +23.48% | -20.96M -68.46% | -36.85M -194.58% | -27.39M -60.64% | -36.33M -107.83% | -121.52M -- |
Net Income Attributable to Common Stockholders | -22.84M -- | -12.44M -- | -12.51M -- | -17.05M -- | -17.48M +23.48% | -20.96M -68.46% | -36.85M -194.58% | -27.39M -60.64% | -36.33M -107.83% | -121.52M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -136.00K -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -17.48M -- | -- -- | -- -- | -- -- | -36.47M -108.60% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -22.84M -- | -12.44M -- | -12.51M -- | -17.05M -- | -17.48M +23.48% | -20.96M -68.46% | -36.85M -194.58% | -27.39M -60.64% | -36.47M -108.60% | -121.66M -- |
Basic EPS | -38.23 -- | -- -- | -18.94 -- | -19.01 -- | -1.6 +95.81% | -0.38 -- | -0.68 +96.41% | -0.5 +97.37% | -0.67 +58.13% | -2.23 -- |
Basic EPS from Continuing Operations | -38.23 -- | -- -- | -18.94 -- | -19.01 -- | -1.6 +95.81% | -- -- | -0.68 +96.41% | -0.5 +97.37% | -0.67 +58.13% | -- -- |
Diluted EPS | -38.23 -- | -- -- | -18.94 -- | -19.01 -- | -1.6 +95.81% | -- -- | -0.68 +96.41% | -0.5 +97.37% | -0.67 +58.13% | -- -- |
Diluted EPS from Continuing Operations | -38.23 -- | -- -- | -18.94 -- | -19.01 -- | -1.6 +95.81% | -- -- | -0.68 +96.41% | -0.5 +97.37% | -0.67 +58.13% | -- -- |
You can ask Aime
Did Bicara Therapeutics beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Bicara Therapeutics year over year?What is Bicara Therapeutics's latest dividend and current dividend yield?What factors drove the changes in Bicara Therapeutics's revenue and profit?What were the key takeaways from Bicara Therapeutics’s earnings call?What does Bicara Therapeutics do and what are its main business segments?What were the key takeaways from Bicara Therapeutics's earnings call?What guidance did Bicara Therapeutics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
